Global Mycoplasma Gallisepticum Inactivated Vaccine Market Growth 2025-2031
Description
The global Mycoplasma Gallisepticum Inactivated Vaccine market size is predicted to grow from US$ 1060 million in 2025 to US$ 1596 million in 2031; it is expected to grow at a CAGR of 7.1% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Mycoplasma gallisepticum inactivated vaccine is a kind of vaccine which is made by Gallisepticum strain culture, inactivation and emulsification with mineral oil adjuvant are biological products mainly used to prevent chronic respiratory disease (CRD) in chickens. They are oil-in-water uniform emulsions and need to pass sterility, safety and efficacy tests to ensure the immunization effect (such as air sac protection rate of immunized chickens ≥ 60%). They are usually injected subcutaneously or intramuscularly and are suitable for chickens over 40 days old. Based on the calculation that the scale of China's animal vaccine industry will exceed RMB 19 billion (about US$2.7 billion) in 2024, poultry inactivated vaccines will account for about 25% (about US$675 million) and China's 20.5% share of the global poultry inactivated vaccine market, coupled with the growing demand for respiratory disease prevention and control in the global poultry farming industry (especially the trend of large-scale farming of laying hens and broilers), the global market size is expected to be around US$1 billion in 2024. In the next three years, it will benefit from the strengthening of biosafety policies (such as the promotion of compulsory immunization), the application of new adjuvant technology (such as nanoemulsion to enhance immunogenicity) and the popularization of vaccines in emerging markets in Africa and Southeast Asia, and is expected to exceed US$1.5 billion in 2031.
United States market for Mycoplasma Gallisepticum Inactivated Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Mycoplasma Gallisepticum Inactivated Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Mycoplasma Gallisepticum Inactivated Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Mycoplasma Gallisepticum Inactivated Vaccine players cover MSD, Merck, Zoetis, Ceva, Bioproperties, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Mycoplasma Gallisepticum Inactivated Vaccine Industry Forecast” looks at past sales and reviews total world Mycoplasma Gallisepticum Inactivated Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Mycoplasma Gallisepticum Inactivated Vaccine sales for 2025 through 2031. With Mycoplasma Gallisepticum Inactivated Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Mycoplasma Gallisepticum Inactivated Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Mycoplasma Gallisepticum Inactivated Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Mycoplasma Gallisepticum Inactivated Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Mycoplasma Gallisepticum Inactivated Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mycoplasma Gallisepticum Inactivated Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mycoplasma Gallisepticum Inactivated Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Mycoplasma Gallisepticum Inactivated Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Bacterial Content Before Inactivation ≥ 110 ccu/ml
Bacterial Content Before Inactivation < 110 ccu/ml
Segmentation by Application:
Agricultural Breeding
Scientific Research
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
MSD
Merck
Zoetis
Ceva
Bioproperties
Pacificvet Limited
Formosa Bio
Qingdao Vland Biotech
Jinyu Bio-Technology
Tianjin Ringpu Bio-technology
ZHAO FENG HUA GROUP
Zhengye Biotechnology Holding
Key Questions Addressed in this Report
What is the 10-year outlook for the global Mycoplasma Gallisepticum Inactivated Vaccine market?
What factors are driving Mycoplasma Gallisepticum Inactivated Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Mycoplasma Gallisepticum Inactivated Vaccine market opportunities vary by end market size?
How does Mycoplasma Gallisepticum Inactivated Vaccine break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Mycoplasma gallisepticum inactivated vaccine is a kind of vaccine which is made by Gallisepticum strain culture, inactivation and emulsification with mineral oil adjuvant are biological products mainly used to prevent chronic respiratory disease (CRD) in chickens. They are oil-in-water uniform emulsions and need to pass sterility, safety and efficacy tests to ensure the immunization effect (such as air sac protection rate of immunized chickens ≥ 60%). They are usually injected subcutaneously or intramuscularly and are suitable for chickens over 40 days old. Based on the calculation that the scale of China's animal vaccine industry will exceed RMB 19 billion (about US$2.7 billion) in 2024, poultry inactivated vaccines will account for about 25% (about US$675 million) and China's 20.5% share of the global poultry inactivated vaccine market, coupled with the growing demand for respiratory disease prevention and control in the global poultry farming industry (especially the trend of large-scale farming of laying hens and broilers), the global market size is expected to be around US$1 billion in 2024. In the next three years, it will benefit from the strengthening of biosafety policies (such as the promotion of compulsory immunization), the application of new adjuvant technology (such as nanoemulsion to enhance immunogenicity) and the popularization of vaccines in emerging markets in Africa and Southeast Asia, and is expected to exceed US$1.5 billion in 2031.
United States market for Mycoplasma Gallisepticum Inactivated Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Mycoplasma Gallisepticum Inactivated Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Mycoplasma Gallisepticum Inactivated Vaccine is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Mycoplasma Gallisepticum Inactivated Vaccine players cover MSD, Merck, Zoetis, Ceva, Bioproperties, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Mycoplasma Gallisepticum Inactivated Vaccine Industry Forecast” looks at past sales and reviews total world Mycoplasma Gallisepticum Inactivated Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Mycoplasma Gallisepticum Inactivated Vaccine sales for 2025 through 2031. With Mycoplasma Gallisepticum Inactivated Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Mycoplasma Gallisepticum Inactivated Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Mycoplasma Gallisepticum Inactivated Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Mycoplasma Gallisepticum Inactivated Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Mycoplasma Gallisepticum Inactivated Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mycoplasma Gallisepticum Inactivated Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mycoplasma Gallisepticum Inactivated Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Mycoplasma Gallisepticum Inactivated Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Bacterial Content Before Inactivation ≥ 110 ccu/ml
Bacterial Content Before Inactivation < 110 ccu/ml
Segmentation by Application:
Agricultural Breeding
Scientific Research
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
MSD
Merck
Zoetis
Ceva
Bioproperties
Pacificvet Limited
Formosa Bio
Qingdao Vland Biotech
Jinyu Bio-Technology
Tianjin Ringpu Bio-technology
ZHAO FENG HUA GROUP
Zhengye Biotechnology Holding
Key Questions Addressed in this Report
What is the 10-year outlook for the global Mycoplasma Gallisepticum Inactivated Vaccine market?
What factors are driving Mycoplasma Gallisepticum Inactivated Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Mycoplasma Gallisepticum Inactivated Vaccine market opportunities vary by end market size?
How does Mycoplasma Gallisepticum Inactivated Vaccine break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
123 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Mycoplasma Gallisepticum Inactivated Vaccine by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Mycoplasma Gallisepticum Inactivated Vaccine by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
